Mounjaro and Clopidogrel Interaction: Safety, Risks, and Monitoring

Does tirzepatide interact with clopidogrel?

Mounjaro's label handles oral medicines as a class. It states that tirzepatide delays gastric emptying and thereby has the potential to affect the absorption of concomitantly administered oral drugs, advises caution, and asks for monitoring of oral drugs that depend on threshold concentrations for efficacy and of those with a narrow therapeutic index, naming warfarin as its example [1]. Clopidogrel is not named in that section [1].

The Mounjaro label reports that tirzepatide is metabolized by cleavage of its peptide backbone, beta-oxidation of its fatty diacid and amide hydrolysis rather than by CYP enzymes, and has low in vitro potential to inhibit or induce CYP enzymes [1]. Clopidogrel is a prodrug: in vitro work found that CYP2C19 accounted for 44.9% of the first oxidative step that forms 2-oxo-clopidogrel and 20.6% of the second step that yields the active metabolite, with CYP1A2, CYP2B6, CYP2C9 and CYP3A4 contributing to the rest [3].

What delayed gastric emptying does to an oral drug

The label quantifies the effect with acetaminophen, not clopidogrel. After a first 5 mg dose of tirzepatide, acetaminophen peak concentration fell 55% and time to peak was about one hour later. By week 6, on 15 mg once weekly, there was no meaningful effect on acetaminophen peak concentration or time to peak, and total exposure (AUC) was unchanged [1]. The label describes the gastric-emptying delay as largest after the first dose and diminishing over time [1].

An oral contraceptive study shows the same pattern with larger peak effects. After a single 5 mg tirzepatide dose, Cmax fell 59% for ethinyl estradiol, 66% for norgestimate and 55% for norelgestromin, while AUC fell 20%, 21% and 23% and time to peak was delayed 2.5 to 4.5 hours [1]. The label advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [1].

Clopidogrel requires hepatic CYP activation to produce an active metabolite that inhibits the platelet P2Y12 receptor [5]. Neither the acetaminophen nor the contraceptive study measured platelet inhibition.

Does tirzepatide affect CYP2C19?

The Mounjaro label describes low in vitro potential to inhibit or induce CYP enzymes, and tirzepatide is metabolized by peptide cleavage, beta-oxidation and amide hydrolysis rather than by CYP enzymes [1].

Other drugs are the better-documented source of CYP-related effects on clopidogrel. Omeprazole reduces clopidogrel responsiveness in pharmacodynamic studies [5]. Whether that translates into clinical events is unsettled: in the COGENT trial, 3,761 analyzed patients taking aspirin plus clopidogrel were randomized to omeprazole or placebo, with GI events of 1.1% vs 2.9% (HR 0.34) and cardiovascular events of 4.9% vs 5.7% (HR 0.99, 95% CI 0.68 to 1.44); the trial stopped early when the sponsor lost financing [6]. A 2011 review concluded there is no consistent evidence that clopidogrel-drug interactions change cardiovascular event rates [5].

CYP2C19 genotype and clopidogrel response

Clopidogrel response varies with CYP2C19 genotype. The CPIC guideline states that CYP2C19 intermediate and poor metabolizers who receive clopidogrel have reduced platelet inhibition and a higher risk of major adverse cardiovascular and cerebrovascular events [2].

Bleeding and gastrointestinal effects

Bleeding is the main hazard of clopidogrel. In CAPRIE, which compared clopidogrel 75 mg with aspirin 325 mg in 19,185 patients with recent ischemic stroke, recent myocardial infarction or symptomatic peripheral arterial disease, clopidogrel lowered the annual risk of ischemic stroke, myocardial infarction or vascular death to 5.32% from 5.83%, a relative risk reduction of 8.7% (p=0.043) [7]; clopidogrel-treated patients had less gastrointestinal haemorrhage than those on aspirin [4].

Mounjaro's labeled adverse reactions are mostly gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain were each reported in 5% or more of patients in the placebo-controlled pool [1]. Severe GI reactions occurred in 1.3% on 5 mg, 0.4% on 10 mg and 1.2% on 15 mg vs 0.9% on placebo, and the label says Mounjaro is not recommended in patients with severe gastroparesis [1]. The label also describes acute kidney injury from volume depletion after GI reactions; it says to monitor renal function in patients who report adverse reactions that could cause volume depletion, especially during dose initiation and escalation [1].

Procedures and sedation

The Mounjaro label notes that pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, and says patients should be instructed to inform healthcare providers of any planned surgeries or procedures [1].